The combination of CPT11 with PLK1 targeting agents was previously assessed in neuroblastoma and colon carcinoma xenografts, although the molecular mechanisms underlying the antitumor efficacy were not elucidated [41, 42]. Here, PLK1 is linked to neuroblastoma.